4.7 Article

Validating γ Oscillations and Delayed Auditory Responses as Translational Biomarkers of Autism

Journal

BIOLOGICAL PSYCHIATRY
Volume 68, Issue 12, Pages 1100-1106

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2010.09.031

Keywords

Animal model; autism; electrophysiology; endophenotype; gamma oscillations; magnetoencephalography (MEG)

Funding

  1. National Institutes of Health [R01-DA023210, T32-MH017168, R01-DC008871]
  2. Nancy Lurie Marks Family Foundation
  3. Autism Speaks
  4. Eli Lilly
  5. AstraZeneca
  6. NuPathe
  7. Pfizer
  8. Merck
  9. Sanofi
  10. Wyeth

Ask authors/readers for more resources

Background: Difficulty modeling complex behavioral phenotypes in rodents (e.g., language) has hindered pathophysiological investigation and treatment development for autism spectrum disorders. Recent human neuroimaging studies, however, have identified functional biomarkers that can be more directly related to the abnormal neural dynamics of autism spectrum disorders. This study assessed the translational potential of auditory evoked-response endophenotypes of autism in parallel mouse and human studies of autism. Methods: Whole-cortex magnetoencephalography was recorded in 17 typically developing and 25 autistic children during auditory pure-tone presentation. Superior temporal gyrus activity was analyzed in time and frequency domains. Auditory evoked potentials were recorded in mice prenatally exposed to valproic acid (VPA) and analyzed with analogous methods. Results: The VPA-exposed mice demonstrated selective behavioral alterations related to autism, including reduced social interactions and ultrasonic vocalizations, increased repetitive self-grooming, and prepulse inhibition deficits. Autistic subjects and VPA-exposed mice showed a similar 10% latency delay in the N1/M100 evoked response and a reduction in gamma frequency (30-50 Hz) phase-locking factor. Electrophysiological measures were associated with mouse behavioral deficits. In mice, gamma phase-locking factor was correlated with expression of the autism risk gene neuroligin-3 and neural deficits were modulated by the mGluR5-receptor antagonist MPEP. Conclusions: Results demonstrate a novel preclinical approach toward mechanistic understanding and treatment development for autism.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available